Literature DB >> 12429309

Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program.

René Raaijmakers1, Wim J Kirkels, Monique J Roobol, Mark F Wildhagen, Fritz H Schrder.   

Abstract

OBJECTIVES: To evaluate the complication rates and possible risk factors of biopsy of the prostate, with the aim of improving patient counseling and the safety of the procedure. Biopsy of the prostate has to be a relatively safe procedure and the participants have to be well informed about the possible complications.
METHODS: Within the biopsy protocol of the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer, we evaluated 5802 transrectal ultrasound-guided systematic sextant biopsies. All participants received prophylactic antibiotic therapy.
RESULTS: We performed 5802 biopsies. Hematuria lasting longer than 3 days and hematospermia were present after 22.6% and 50.4% of the procedures, respectively. More severe complications were far less frequent. Two hundred participants (3.5%) developed fever after biopsy. Urinary retention was seen 20 times (0.4%), and hospitalization was needed in 27 cases (0.5%). Twenty-five of these men were admitted because of signs of prostatitis and/or urosepsis. Risk factor analyses revealed that an earlier episode of prostatitis was significantly associated with hospital admission and pain after biopsy. Characteristics of prostatic hyperplasia, such as prostate volume, transition zone volume/total prostate volume ratio, and a higher International Prostate Symptom Score, were all predictors of urinary retention.
CONCLUSIONS: Minor complications are frequently seen but major complications are rare after prostate biopsy. Assessment of the risk factors before biopsy can help to improve the adequacy of counseling, and precautionary measures can be taken to minimize the risk of complications after the procedure. Transrectal ultrasound-guided sextant biopsy remains a safe procedure for the diagnosis of prostate cancer within the general population.

Entities:  

Mesh:

Year:  2002        PMID: 12429309     DOI: 10.1016/s0090-4295(02)01958-1

Source DB:  PubMed          Journal:  Urology        ISSN: 0090-4295            Impact factor:   2.649


  80 in total

1.  [Complications of transrectal prostate biopsy. Determination of current status].

Authors:  H W Gottfried; B Volkmer
Journal:  Urologe A       Date:  2003-08       Impact factor: 0.639

2.  Priorities in future research in prostate cancer screening.

Authors:  Fritz H Schröder
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

3.  Furthering the prostate cancer screening debate (prostate cancer specific mortality and associated risks).

Authors:  G Michael Allan; Michael P Chetner; Bryan J Donnelly; Neil A Hagen; David Ross; J Dean Ruether; Peter Venner
Journal:  Can Urol Assoc J       Date:  2011-12       Impact factor: 1.862

4.  CUA guidelines on prostate biopsy methodology.

Authors:  Assaad El-Hakim; Sabri Moussa
Journal:  Can Urol Assoc J       Date:  2010-04       Impact factor: 1.862

Review 5.  [Prostate biopsy: Procedure in the clinical routine].

Authors:  T Enzmann; T Tokas; K Korte; M Ritter; P Hammerer; L Franzaring; H Heynemann; H-W Gottfried; H Bertermann; M Meyer-Schwickerath; B Wirth; A Pelzer; T Loch
Journal:  Urologe A       Date:  2015-12       Impact factor: 0.639

6.  Discontinuation of anticoagulant or antiplatelet therapy for transrectal ultrasound-guided prostate biopsies: a single-center experience.

Authors:  Omer A Raheem; Rowan G Casey; David J Galvin; Rustom P Manecksha; Haradikar Varadaraj; Ted McDermott; Ronald Grainger; Thomas H Lynch
Journal:  Korean J Urol       Date:  2012-04-18

7.  Time of administration of a single dose of oral levofloxacin and its effect in infectious complications from transrectal prostate biopsy.

Authors:  Athanasios N Argyropoulos; Konstantinos Doumas; Antonios Farmakis; Ioannis Liakatas; Ioannis Gkialas; Michael Lykourinas
Journal:  Int Urol Nephrol       Date:  2007-01-04       Impact factor: 2.370

8.  Endoclipping treatment of life-threatening rectal bleeding after prostate biopsy.

Authors:  Panagiotis Katsinelos; Jannis Kountouras; Georgios Dimitriadis; Grigoris Chatzimavroudis; Christos Zavos; Ioannis Pilpilidis; George Paroutoglou; George Germanidis; Kostas Mimidis
Journal:  World J Gastroenterol       Date:  2009-03-07       Impact factor: 5.742

9.  Prospective evaluation of the safety of transrectal ultrasound-guided transperineal prostate biopsy based on adverse events.

Authors:  Takeshi Namekawa; Satoshi Fukasawa; Atsushi Komaru; Masayuki Kobayashi; Yusuke Imamura; Takayuki Ohzeki; Kimiaki Takagi; Yosuke Sato; Koichiro Akakura; Tomohiko Ichikawa; Takeshi Ueda
Journal:  Int J Clin Oncol       Date:  2015-04-28       Impact factor: 3.402

10.  Prostate cancer screening characteristics in men with BRCA1/2 mutations attending a high-risk prevention clinic.

Authors:  Richard Walker; Alyssa Louis; Alejandro Berlin; Sheri Horsburgh; Robert G Bristow; John Trachtenberg
Journal:  Can Urol Assoc J       Date:  2014-11       Impact factor: 1.862

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.